CD79A and cancer: VCA IgG appeared consistently more frequent in cancer patients than in controls, but only 1 Japanese study from 1991 had reported a significant difference in the EBV seropositivity between cases and controls, using IFA to detect VCA IgG at the cutoff >1:640 (OR = 22.2, 95% CI 7.8–63.1).19 Additionally, inconsistent results and absence of differences between cases and control were reported for VCA IgA, EA IgG, EA-D IgG, and EA-R IgG.